Validation of New Biomarkers for Monitoring P. falciparum Reduced susceptibility/Tolerance or Resistance to Artemisinin Derivatives and Partner Drugs

Conditions

Malaria

Akintunde Sowunmi, Godwin Ntadom, Kazeem Akano, Folasade O. Ibironke, Adejumoke Idowu Ayede et al. (36 authors)

Infectious Diseases of Poverty2019-08-0619 citations

Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments.

Sowunmi A, Akano K, Ntadom G, Ayede AI, Ibironke FO, Aderoyeje T, Adewoye EO, Fatunmbi B, Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Folarin OA, Gbotosho GO, Happi CT.

2017-02-0712 citations

10.1186/s40249-016-0217-7

Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria

Akintunde Sowunmi, Kazeem Akano, Adejumoke Idowu Ayede, Elsie O. Adewoye, Godwin Ntadom et al. (9 authors)

BMC Infectious Diseases2017-01-317 citations

10.1186/s12879-016-2173-z

Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Adewoye EO, Fatunmbi B, Aderoyeje T.

2016-07-065 citations

10.1186/s40249-016-0165-2

Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Aderoyeje T, Adewoye EO, Fatunmbi B.

2016-06-0111 citations

10.1186/s12879-016-1565-4

Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Fatunmbi B, Aderoyeje T, Adewoye EO.

2015-10-2610 citations

10.1186/s12879-015-1219-y

Interventions

artemether plus lumefantrine

artesunate plus amodiaquine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptoms compatible with acute uncomplicated malaria with pure Plasmodium falciparum parasitemia. Microscopically confirmed P. falciparum infection with parasite density ¿ 2,000/¿l of blood Body (axillary) temperature > 37.4oC or history of fever 24 ¿ 48 hours preceding presentation. No have other concomitant illness. No history of antimalarial use in the two weeks preceding presentation. Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule. Written informed consent given by parents or guardians.

Exclusion criteria

Exclusion criteria: Severe malaria Severe malnutrition. Serious underlying disease (renal, cardiac, hepatic) Concomitant febrile illness. Known allergy to study drug or its components.

Design outcomes

Primary

Measure	Time frame
Clinical outcome (cured or treatment failures)	—

Secondary

Measure	Time frame
Parasites reduction ratio;Parasites and fever clearance times;Blood drugs levels;in vitro susceptibility profiles of parasites from patient isolates;Mutations/haplotypes in transporter Plasmodium falciparum transporter genes	—

Countries

Nigeria

Contacts

Public ContactGrace Olusola Gbotosho

Professor

solagbotosho@yahoo.co.uk08030757071

Outcome results

None listed